Palivizumab - Drugbank

11/22/2018 Palivizumab - DrugBank

Palivizumab

Targets (11)

IDENTIFICATION

Name Palivizumab

Accession Number

DB00110 (BTD00097, BIOD00097)

Type

Biotech

Groups

Approved, Investigational

Biologic Classiﬁcation

Protein Based Therapies Monoclonal antibody (mAb)

Description

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)

Protein structure

https://www.drugbank.ca/drugs/DB00110 1/22 11/22/2018 Palivizumab - DrugBank

Protein chemical formula Not Available

Protein average weight Not Available

Sequences

>VH region MEDI-493 QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKD YNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS

>VH Region QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGWIRQPPGKALEWLADIWWDDKKD YNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARSMITNWYFDVWGAGTTVTVSS

Download FASTA Format

Synonyms

anti-RSV

Prescription Products

MARKETING MARKETING NAME ↑↓ DOSAGE ↑↓ STRENGTH ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Synagis Injection, 100 mg/mL Intramuscular Abb Vie 1999-08-13 Not applicable solution Deutschland Gmb H & Co. Kg

Synagis Injection, 50 mg Intramuscular Abb Vie 1999-08-13 Not applicable powder, for Deutschland solution Gmb H & Co. Kg

Synagis Injection 100 mg/1mL Intramuscular MedImmune 1998-06-19 Not applicable https://www.drugbank.ca/drugs/DB00110 2/22 11/22/2018 Palivizumab - DrugBank Synagis Injection, 100 mg/1mL Intramuscular MedImmune, 1998 06 19 Not applicable solution LLC MARKETING MARKETING NAME ↑↓ DOSAGE ↑↓ STRENGTH ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓ Synagis Solution 50 mg Intramuscular Abbvie 2016-11-03 Not applicable

Synagis Injection, 100 mg/mL Intramuscular Abb Vie 1999-08-13 Not applicable solution Deutschland Gmb H & Co. Kg

Synagis Powder, for 100 mg Intramuscular Abbvie 2002-09-26 Not applicable solution

Synagis Solution 100 mg Intramuscular Abbvie 2016-11-03 Not applicable

Synagis Injection, 100 mg Intramuscular Abb Vie 1999-08-13 Not applicable powder, for Deutschland solution Gmb H & Co. Kg

Synagis Injection, 50 mg/0.5mL Intramuscular MedImmune, 1999-12-09 Not applicable solution LLC

Synagis Powder, for 50 mg Intramuscular Abbvie 2002-09-26 Not applicable solution

Showing 1 to 10 of 10 entries ‹ ›

International/Other Brands

Synagis

Categories

Amino Acids, Peptides, and Proteins

Anti-Infective Agents

Antibodies

Antibodies, Monoclonal

Antibodies, Monoclonal, Humanized

Antiinfectives for Systemic Use

Antiviral Agents

Blood Proteins

Fusion Protein Inhibitors

Globulins

Immune Sera and Immunoglobulins https://www.drugbank.ca/drugs/DB001l b li 10 3/22 11/22/2018 Palivizumab - DrugBank Immunoglobulins

Immunoproteins

Proteins

Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

Serum Globulins

Speciﬁc Immunoglobulins

UNII DQ448MW7KS

CAS number

188039-54-5

PHARMACOLOGY

Indication For prophylaxis of respiratory diseases casued by respiratory syncytial virus.

Associated Conditions

Infections, Respiratory Syncytial Virus

Pharmacodynamics Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.

Mechanism of action Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.

A Fusion glycoprotein F0

Not Available

Human respiratory syncytial virus B (strain 18537)

U Low aﬃnity immunoglobulin gamma Fc region receptor III-B

Not Available

Human

Complement C1r subcomponent https://www.drugbank.ca/drugs/DB00110 4/22 11/22/2018 Palivizumab - DrugBank U Complement C1r subcomponent

Not Available

Human

U Complement C1q subcomponent subunit A

Not Available

Human

U Complement C1q subcomponent subunit B

Not Available

Human

U Complement C1q subcomponent subunit C

Not Available

Human

U Low aﬃnity immunoglobulin gamma Fc region receptor III-A

Not Available

Human

U High aﬃnity immunoglobulin gamma Fc receptor I

Not Available

Human

U Low aﬃnity immunoglobulin gamma Fc region receptor II-a

Not Available

Human

U Low aﬃnity immunoglobulin gamma Fc region receptor II-b

Not Available

Human

U Low aﬃnity immunoglobulin gamma Fc region receptor II-c

Not Available

Human

Absorption Not Available

Volume of distribution

Not Available

Protein binding https://www.drugbank.ca/drugs/DB00110 5/22 11/22/2018 Palivizumab - DrugBank

Not Available

Metabolism

Most likely removed by opsonization via the reticuloendothelial system.

Route of elimination Not Available

Half life 18-20 days (in adults)

Clearance

Not Available

Toxicity

Not Available

Aﬀected organisms Not Available

Pathways Not Available

Pharmacogenomic Eﬀects/ADRs

Not Available

INTERACTIONS

Drug Interactions

ALL DRUGS APPROVED VET APPROVED NUTRACEUTICAL ILLICIT WITHDRAWN

INVESTIGATIONAL EXPERIMENTAL

DRUG ↑↓ INTERACTION ↑↓ https://www.drugbank.ca/drugs/DB00110 6/22 11/22/2018 Palivizumab - DrugBank

DRUG ↑↓ INTERACTION ↑↓ Abciximab The risk or severity of adverse eﬀects can be increased when Abciximab is combined with Palivizumab.

Abituzumab The risk or severity of adverse eﬀects can be increased when Palivizumab is combined with Abituzumab.

Adalimumab The risk or severity of adverse eﬀects can be increased when Adalimumab is combined with Palivizumab.

Adecatumumab The risk or severity of adverse eﬀects can be increased when Palivizumab is combined with Adecatumumab.

Aducanumab The risk or severity of adverse eﬀects can be increased when Palivizumab is combined with Aducanumab.

Afelimomab The risk or severity of adverse eﬀects can be increased when Palivizumab is combined with Afelimomab.

Alemtuzumab The risk or severity of adverse eﬀects can be increased when Alemtuzumab is combined with Palivizumab.

Alirocumab The risk or severity of adverse eﬀects can be increased when Palivizumab is combined with Alirocumab.

Amatuximab The risk or severity of adverse eﬀects can be increased when Palivizumab is combined with Amatuximab.

AMG 108 The risk or severity of adverse eﬀects can be increased when Palivizumab is combined with AMG 108.

Showing 1 to 10 of 239 entries ‹ ›

Food Interactions Not Available

REFERENCES

General References

Not Available

External Links PubChem Substance 46506637

ChEMBL CHEMBL1201586

Therapeutic Targets Database https://www.drugbank.ca/drugs/DB00110 7/22 11/22/2018 Palivizumab - DrugBank DAP000386

PharmGKB PA164748781

RxList RxList Drug Page

Drugs.com Drugs.com Drug Page

Wikipedia Palivizumab

ATC Codes J06BB16 — Palivizumab J06BB — Speciﬁc immunoglobulins J06B — IMMUNOGLOBULINS J06 — IMMUNE SERA AND IMMUNOGLOBULINS J — ANTIINFECTIVES FOR SYSTEMIC USE

AHFS Codes

08:18.24 — Monoclonal Antibodies

FDA label

Download (36.1 KB)

CLINICAL TRIALS

Clinical Trials

PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓ 1, 2 Completed Prevention Motavizumab Administration for a Second Season for 1 RSV Prophylaxis

2 Completed Prevention Chronic Lung Disease and <= 24 Months of Age or / 1 Infections, Respiratory Syncytial Virus / Premature With Gestational Age <=35 Weeks and <=6 Months of Age

2 Completed Prevention Congenital Heart Disease (CHD) 1

2 Completed Treatment Unhealthy Children With a History of Prematurity 1 https://www.drugbank.ca/drugs/DB00110 8/22 11/22/2018 Palivizumab - DrugBank

PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓

2, 3 Completed Prevention Chronic Lung Disease of Prematurity / Congenital Heart 1 Disease (CHD) / Infections, Respiratory Syncytial Virus / Premature Births

3 Completed Prevention Infections, Respiratory Syncytial Virus 2

3 Completed Supportive Malignancies 1 Care

3 Completed Treatment Respiratory Syncytial Virus (RSV) 1

3 Completed Treatment Respiratory Syncytial Virus-bronchiolitis 1

4 Completed Treatment Chronic Lung Diseases 1

Showing 1 to 10 of 11 entries ‹ ›

PHARMACOECONOMICS

Manufacturers

Not Available

Packagers

Abbott Laboratories Ltd.

Medimmune Inc.

Dosage forms

FORM ↑↓ ROUTE ↑↓ STRENGTH ↑↓ Injection, powder, for solution Intramuscular 100 mg

Injection, powder, for solution Intramuscular 50 mg

Injection, solution Intramuscular 100 mg/1mL

Injection, solution Intramuscular 100 mg/mL

Injection, solution Intramuscular 50 mg/0.5mL

Powder, for solution Intramuscular 100 mg

Powder, for solution Intramuscular 50 mg

Solution Intramuscular 100 mg

Solution Intramuscular 50 mg

https://www.drugbank.ca/drugs/DB00110 9/22 11/22/2018 Palivizumab - DrugBank Showing 1 to 9 of 9 entries ‹ ›

Prices Not Available

Patents

PATENT NUMBER ↑↓ PEDIATRIC EXTENSION ↑↓ APPROVED ↑↓ EXPIRES (ESTIMATED) ↑↓ ↑↓

CA2197684 No 2000-10-31 2015-08-09

Showing 1 to 1 of 1 entries ‹ ›

PROPERTIES

State Liquid

Experimental Properties

PROPERTY VALUE SOURCE

melting point 61 °C (FAB fragment), 71 °C (whole Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (°C) mAb) (2000)

TAXONOMY

Description Not Available

Kingdom Organic Compounds

Super Class Organic Acids

Class Carboxylic Acids and Derivatives https://www.drugbank.ca/drugs/DB00110 10/22 11/22/2018 Palivizumab - DrugBank

Sub Class

Amino Acids, Peptides, and Analogues

Direct Parent Peptides

Alternative Parents Not Available

Substituents Not Available

Molecular Framework Not Available

External Descriptors Not Available

TARGETS

1. Fusion glycoprotein F0

Kind Protein

Organism Human respiratory syncytial virus B (strain 18537)

Pharmacological action

Yes General Function Not Available

Speciﬁc Function

During virus entry, induces fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. The fusogenic activity is inactive untill entry into host cell endosom...

G N https://www.drugbank.ca/drugs/DB00110 11/22 11/22/2018 Palivizumab - DrugBank Gene Name

Uniprot ID

P13843

Uniprot Name Fusion glycoprotein F0

Molecular Weight 63687.815 Da

References

1. Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H: Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010 Aug;84(16):8132-40. doi: 10.1128/JVI.02699-09. Epub 2010 Jun 2. [PubMed:20519399] 2. Wu H, Pfarr DS, Losonsky GA, Kiener PA: Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103-23. [PubMed:17990791] 3. Robinson KA, Odelola OA, Saldanha I, McKoy N: Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic ﬁbrosis. Cochrane Database Syst Rev. 2010 Feb 17; (2):CD007743. doi: 10.1002/14651858.CD007743.pub2. [PubMed:20166098]

2. Low aﬃnity immunoglobulin gamma Fc region receptor III-B

Kind

Protein

Organism Human

Pharmacological action

Unknown General Function Not Available

Speciﬁc Function

Receptor for the Fc region of immunoglobulins gamma. Low aﬃnity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent...

Gene Name

FCGR3B

https://www.drugbank.ca/drugs/DB00110 12/22 11/22/2018 Palivizumab - DrugBank Uniprot ID O75015

Uniprot Name

Low aﬃnity immunoglobulin gamma Fc region receptor III-B

Molecular Weight

26215.64 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284] 2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

3. Complement C1r subcomponent

Kind

Protein

Organism

Human

Pharmacological action

Unknown General Function

Serine-type peptidase activity

Speciﬁc Function

C1r B chain is a serine protease that combines with C1q and C1s to form C1, the ﬁrst component of the classical pathway of the complement system.

Gene Name C1R

Uniprot ID

P00736

Uniprot Name

Complement C1r subcomponent

Molecular Weight https://www.drugbank.ca/drugs/DB00110 13/22 11/22/2018 Palivizumab - DrugBank 80118.04 Da

References

4. Complement C1q subcomponent subunit A

Kind

Protein

Organism

Human

Pharmacological action

Unknown General Function

Not Available

Speciﬁc Function

C1q associates with the proenzymes C1r and C1s to yield C1, the ﬁrst component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proe...

Gene Name C1QA

Uniprot ID P02745

Uniprot Name

Complement C1q subcomponent subunit A

Molecular Weight

26016.47 Da

References

1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]

https://www.drugbank.ca/drugs/DB00110 14/22 11/22/2018 Palivizumab - DrugBank 2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

5. Complement C1q subcomponent subunit B

Kind

Protein

Organism

Human

Pharmacological action

Unknown General Function Not Available

Speciﬁc Function

Gene Name

C1QB

Uniprot ID

P02746

Uniprot Name Complement C1q subcomponent subunit B

Molecular Weight

26721.62 Da

References

6. Complement C1q subcomponent subunit C https://www.drugbank.ca/drugs/DB00110 15/22 11/22/2018 Palivizumab - DrugBank

Kind Protein

Organism

Human

Pharmacological action

Unknown General Function

Not Available

Speciﬁc Function C1q associates with the proenzymes C1r and C1s to yield C1, the ﬁrst component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proe...

Gene Name C1QC

Uniprot ID

P02747

Uniprot Name

Complement C1q subcomponent subunit C

Molecular Weight 25773.56 Da

References

7. Low aﬃnity immunoglobulin gamma Fc region receptor III-A

Kind

Protein

Organism Human https://www.drugbank.ca/drugs/DB00110 16/22 11/22/2018 Palivizumab - DrugBank

Pharmacological action

Unknown General Function Not Available

Speciﬁc Function

Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as...

Gene Name

FCGR3A

Uniprot ID P08637

Uniprot Name Low aﬃnity immunoglobulin gamma Fc region receptor III-A

Molecular Weight

29088.895 Da

References

8. High aﬃnity immunoglobulin gamma Fc receptor I

Kind

Protein

Organism

Human

Pharmacological action

Unknown General Function

Receptor signaling protein activity

https://www.drugbank.ca/drugs/DB00110 17/22 11/22/2018 Palivizumab - DrugBank Speciﬁc Function

High aﬃnity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.

Gene Name FCGR1A

Uniprot ID

P12314

Uniprot Name

High aﬃnity immunoglobulin gamma Fc receptor I

Molecular Weight 42631.525 Da

References

9. Low aﬃnity immunoglobulin gamma Fc region receptor II-a

Kind Protein

Organism Human

Pharmacological action

Unknown General Function

Not Available

Speciﬁc Function

Binds to the Fc region of immunoglobulins gamma. Low aﬃnity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized ...

Gene Name

FCGR2A https://www.drugbank.ca/drugs/DB00110 18/22 11/22/2018 Palivizumab - DrugBank

Uniprot ID P12318

Uniprot Name

Low aﬃnity immunoglobulin gamma Fc region receptor II-a

Molecular Weight

35000.42 Da

References

10. Low aﬃnity immunoglobulin gamma Fc region receptor II-b

Kind Protein

Organism

Human

Pharmacological action

Unknown General Function Not Available

Speciﬁc Function

Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low aﬃnity receptor. Involved in a variety of eﬀector and regulatory functions such as phagocytosis of immune complex...

Gene Name

FCGR2B

Uniprot ID

P31994

Uniprot Name Low aﬃnity immunoglobulin gamma Fc region receptor II-b

https://www.drugbank.ca/drugs/DB00110 19/22 11/22/2018 Palivizumab - DrugBank Molecular Weight

34043.355 Da

References

11. Low aﬃnity immunoglobulin gamma Fc region receptor II-c

Kind

Protein

Organism

Human

Pharmacological action

Unknown General Function Transmembrane signaling receptor activity

Specific Function Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulat...

Gene Name

FCGR2C

Uniprot ID

P31995

Uniprot Name

Low aﬃnity immunoglobulin gamma Fc region receptor II-c

Molecular Weight 35577.96 Da

References

1 O i t JP Al L ik i B H ki AL H d t t th ? N t R D Di 2006 https://www.drugbank.ca/drugs/DB00110 20/22 11/22/2018 Palivizumab - DrugBank 1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284] 2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on November 21, 2018 09:58

About

About DrugBank

DrugBank Blog Wishart Research Group

Support

FAQ Help

Email Support

Commercial Products API Pricing

API Docs Data Licenses

Support

This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-proﬁt organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc.

https://www.drugbank.ca/drugs/DB00110 21/22 11/22/2018 Palivizumab - DrugBank

https://www.drugbank.ca/drugs/DB00110 22/22